PMID- 27124044
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 17
DP  - 2016 Apr
TI  - Prognostic Factors Toward Clinically Relevant Radiographic Progression in 
      Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, 
      Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy.
PG  - e3476
LID - 10.1097/MD.0000000000003476 [doi]
LID - e3476
AB  - To determine prognostic factors of clinically relevant radiographic progression 
      (CRRP) in patients with rheumatoid arthritis (RA) in clinical practice.We 
      performed a multicenter prospective study in Japan of biological 
      disease-modifying antirheumatic drug (bDMARD)-naive RA patients with moderate to 
      high disease activity treated with conventional synthetic DMARDs (csDMARDs) at 
      study entry. We longitudinally observed 408 patients for 1 year and assessed 
      disease activity every 3 months. CRRP was defined as yearly progression of 
      modified total Sharp score (mTSS) > 3.0 U. We also divided the cohort into 2 
      groups based on disease duration (<3 vs >/=3 years) and performed a subgroup 
      analysis.CRRP was found in 10.3% of the patients. A multiple logistic regression 
      analysis revealed that the independent variables to predict the development of 
      CRRP were: CRP at baseline (0.30 mg/dL increase, 95% confidence interval [CI] 
      1.01-1.11), time-integrated Disease Activity Score in 28 joints-erythrocyte 
      sedimentation rate (DAS28-ESR) during the 1 year postbaseline (12.4-unit 
      increase, 95%CI 1.17-2.59), RA typical erosion at baseline (95%CI 1.56-21.1), and 
      the introduction of bDMARDs (95%CI 0.06-0.38). The subgroup analysis revealed 
      that time-integrated DAS28-ESR is not a predictor whereas the introduction of 
      bDMARDs is a significant protective factor for CRRP in RA patients with disease 
      duration <3 years.We identified factors that could be used to predict the 
      development of CRRP in RA patients treated with DMARDs. These variables appear to 
      be different based on the RA patients' disease durations.
FAU - Koga, Tomohiro
AU  - Koga T
AD  - From the Unit of Translational Medicine, Department of Immunology and 
      Rheumatology, Nagasaki University Graduate School of Biomedical Sciences (TK,YH, 
      S-YK, NI, KI, MT, HN, AK); Japanese Red Cross Nagasaki Genbaku Hospital, 
      Department of Rheumatology, Nagasaki (AO, MN, TA); Department of Rheumatology, 
      Kurume University Medical Center, Kurume (TF, MN); Zenjinkai Shimin-no-Mori 
      Hospital, Miyazaki (TH); Department of Hematology and Rheumatology, Tohoku 
      University Hospital, Sendai (TI, RW); Rheumatic and Collagen Disease Center, 
      Sasebo Chuo Hospital, Sasebo (YU); Tohoku Pharmaceutical University Hospital, 
      Sendai (TK); Yu Family Clinic, Miyagi (YT); Kurume University School of Medicine, 
      Kurume (SH); Department of Orthopaedic Surgery, Tohoku University Hospital (HO); 
      East Sendai Rheumatism and Internal Medicine Clinic, Sendai (TI); Osaki Citizen 
      Hospital, Osaki (OT); NHO Nagasaki Medical Center, Omura (TM); Clinical Research 
      Center, Nagasaki University Hospital (SS); Department of Public Health (S-YK, 
      KA); Department of Rehabilitation Sciences, Nagasaki University Graduate School 
      of Biomedical Sciences, Nagasaki (TO); and Sasebo City General Hospital, Sasebo 
      (KE), Japan.
FAU - Okada, Akitomo
AU  - Okada A
FAU - Fukuda, Takaaki
AU  - Fukuda T
FAU - Hidaka, Toshihiko
AU  - Hidaka T
FAU - Ishii, Tomonori
AU  - Ishii T
FAU - Ueki, Yukitaka
AU  - Ueki Y
FAU - Kodera, Takao
AU  - Kodera T
FAU - Nakashima, Munetoshi
AU  - Nakashima M
FAU - Takahashi, Yuichi
AU  - Takahashi Y
FAU - Honda, Seiyo
AU  - Honda S
FAU - Horai, Yoshiro
AU  - Horai Y
FAU - Watanabe, Ryu
AU  - Watanabe R
FAU - Okuno, Hiroshi
AU  - Okuno H
FAU - Aramaki, Toshiyuki
AU  - Aramaki T
FAU - Izumiyama, Tomomasa
AU  - Izumiyama T
FAU - Takai, Osamu
AU  - Takai O
FAU - Miyashita, Taiichiro
AU  - Miyashita T
FAU - Sato, Shuntaro
AU  - Sato S
FAU - Kawashiri, Shin-Ya
AU  - Kawashiri SY
FAU - Iwamoto, Naoki
AU  - Iwamoto N
FAU - Ichinose, Kunihiro
AU  - Ichinose K
FAU - Tamai, Mami
AU  - Tamai M
FAU - Origuchi, Tomoki
AU  - Origuchi T
FAU - Nakamura, Hideki
AU  - Nakamura H
FAU - Aoyagi, Kiyoshi
AU  - Aoyagi K
FAU - Eguchi, Katsumi
AU  - Eguchi K
FAU - Kawakami, Atsushi
AU  - Kawakami A
CN  - Japanese RA Patients with RRP Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Autoantibodies)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*diagnostic imaging/*drug therapy/immunology
MH  - Autoantibodies/blood
MH  - Blood Sedimentation
MH  - C-Reactive Protein/analysis
MH  - Cohort Studies
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Japan
MH  - Joints/diagnostic imaging
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement
MH  - Prospective Studies
MH  - Risk
PMC - PMC4998707
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2016/04/29 06:00
MHDA- 2017/01/31 06:00
PMCR- 2016/04/29
CRDT- 2016/04/29 06:00
PHST- 2016/04/29 06:00 [entrez]
PHST- 2016/04/29 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
PHST- 2016/04/29 00:00 [pmc-release]
AID - 00005792-201604260-00032 [pii]
AID - 10.1097/MD.0000000000003476 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Apr;95(17):e3476. doi: 10.1097/MD.0000000000003476.